Targeting desmoplasia in pancreatic cancer as an essential first step to effective therapy
Metrics: PDF 1075 views | Full Text 1827 views | ?
Nancy D. Ebelt1, Vic Zamloot1 and Edwin R. Manuel1
1 Department of Immuno-Oncology, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA
|Edwin R. Manuel,||email:||[email protected]|
Keywords: pancreatic cancer; desmoplasia; fibrosis; hyaluronan; collagen
Received: June 22, 2020 Accepted: August 26, 2020 Published: September 22, 2020
Pancreatic cancer is considered one of the most lethal cancers in the US. It contributes to an estimated 47,000 deaths annually and is predicted to surpass prostate, breast and colorectal cancers as the leading cause of cancer-related death. Although major advancements in cancer treatment have improved outcomes for many cancer types, survival rate for pancreatic cancer has not improved in nearly four decades despite tremendous effort. One attribute of pancreatic cancer that is considered a major barrier to effective treatment is the formation of fibrotic tissue around tumor cells known as desmoplasia. A number of promising approaches have been developed to deplete fibrotic components in pancreatic tumors to enhance drug delivery, some of which have been tested in clinical trials of advanced, unresectable pancreatic cancer. Here, we discuss previous efforts, shortcomings and new considerations for developing more effective agents to eliminate desmoplasia.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.